What is a core aspect of hepatorenal syndrome management?

Prepare for Liver Disease and Tumors Test with tailored flashcards and questions. Get detailed explanations and improve your knowledge. Ace the medical student exam!

Hepatorenal syndrome hinges on a circulatory problem: widespread splanchnic vasodilation reduces effective arterial blood volume, triggering renal vasoconstriction and a fall in GFR. The most effective initial management targets this physiology by expanding intravascular volume and increasing systemic vascular resistance. Administering albumin helps restore circulating volume and improves renal perfusion, while a vasoconstrictor agent counteracts the splanchnic vasodilation to boost renal blood flow. Using norepinephrine or a combination such as octreotide with midodrine (and sometimes other vasoconstrictors) specifically addresses the poor renal perfusion driving HRS and can reverse the dysfunction, sometimes serving as a bridge to liver transplantation. Dialysis alone doesn’t correct the underlying hemodynamics and is not a definitive treatment. Corticosteroids aren’t first-line for HRS, and immediate liver resection isn’t appropriate in the context of advanced liver failure. The definitive long-term solution is liver transplantation, but the cornerstone of initial management is albumin plus vasoconstrictors.